Marx D, Fattahi-Meibodi A, Kudelka R, Uebel T, Kuhn W, Meden H
Department of Obstetrics and Gynecology, University of Göttingen, Germany.
Anticancer Res. 1998 Jul-Aug;18(4B):2891-4.
Immunohistochemical detection of the oncogene c-erbB-2 (HER2/neu) has been shown to be an important prognostic marker in ovarian cancer. In this study we evaluated a new developed polyclonal detector antibody-based ELISA for the extracellular domain of p185 to determine whether the soluble oncoprotein fragment p105 can be detected in the serum of ovarian cancer patients.
The relationship between p105 serum levels and various tumor parameters in 53 patients with newly diagnosed, untreated ovarian cancer was studied. Serum specimens were obtained prior initial surgery, and p105 levels were determined using a new developed, polyclonal detector antibody-based human neu quantitative ELISA assay.
Using the polyclonal detector antibody-based ELISA, elevated p105 serum levels were not related to tumor stage, grade, histology and residual tumor after primary surgery.
These results suggest that particular statements concerning the preoperatively taken p105 level using the polyclonal antibody-based ELISA in patients with primary ovarian cancer cannot be brawn yet.
癌基因c-erbB-2（HER2/neu）的免疫组织化学检测已被证明是卵巢癌的一个重要预后标志物。在本研究中，我们评估了一种新开发的基于多克隆检测抗体的ELISA法，用于检测p185细胞外结构域，以确定是否能在卵巢癌患者血清中检测到可溶性癌蛋白片段p105。
研究了53例新诊断、未治疗的卵巢癌患者血清p105水平与各种肿瘤参数之间的关系。在初次手术前采集血清标本，使用新开发的基于多克隆检测抗体的人neu定量ELISA法测定p105水平。
使用基于多克隆检测抗体的ELISA法，血清p105水平升高与肿瘤分期、分级、组织学及初次手术后残留肿瘤无关。
这些结果表明，对于原发性卵巢癌患者，使用基于多克隆抗体的ELISA法术前检测p105水平，目前还不能得出特定结论。
